Metformin controlled-release/sitagliptin - Merck

Drug Profile

Metformin controlled-release/sitagliptin - Merck

Alternative Names: Januet XR; Janumet XR; MK-0431A XR; Sitagliptin/metformin HCl extended-release; Sitagliptin/metformin hydrochloride extended-release

Latest Information Update: 31 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Antihyperglycaemics; Biguanides; Insulin sensitisers; Pyrazines; Small molecules; Triazoles
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 31 Aug 2017 Phase-III development for Type-2 diabetes mellitus (In adolescents, In children) is ongoing in countries worldwide (PO) (NCT01760447) (EudraCT2012-004035-23)
  • 31 Aug 2017 Phase-III clinical trials in Type-2 diabetes mellitus (In adolescents, In children) in Moldova, Mauritius, Greece, Guatemala and Georgia (PO) before August 2017 (NCT01760447)
  • 07 Apr 2017 Merck receives complete response letter from the FDA for metformin controlled-release/sitagliptin treatment of patients with Type 2 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top